[1] Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group[J]. Blood, 2009, 113(11): 2386-2393.[2] Yeh H, Moore D J, Markmann J F, et al. Mechanisms of regulatory T cell counter-regulation by innate immunity[J]. Transplant Rev (Orlando), 2013, 27(2): 61-64.[3] Janson P C, Winerdal M E, Marits P, et al. FOXP3 promoter demethylation reveals the committed Treg population in humans[J]. PLoS One, 2008, 3(2): e1612.[4] Lee S M, Gao B, Fang D. FoxP3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1[J]. Blood, 2008, 111(7): 3599-3606.[5] Wang J D, Chang T K, Lin H K, et al. Reduced expression of transforming growth factor-β1 and correlated elevation of interleukin-17 and interferon-γ in pediatric patients with chronic primary immune thrombocytopenia (ITP)[J]. Pediatr Blood Cancer,2011,57(4): 636-640.[6] Aboul-Fotoh Lel-M, Abdel Raheem M M, El-Deen M A, et al. Role of CD4+ CD25+ T cells in children with idiopathic thrombocytopenic purpura[J]. Pediatr Hematol Oncol, 2011, 33(2): 81-85.[7] Zahran A M, Elsayh K I. CD4+ CD25+ High Foxp3+regulatory T Cells, B lymphocytes, and T lymphocytes in patients with acute ITP in Assiut children Hospital[J]. Clin Appl Thromb Hemost,2014,20(1):61-67.[8] Stelmaszczyk-Emmel A, Jackowska T, Rutkowska-Sak L, et al. Identification, frequency, activation and function of CD4+ CD25(high)FoxP3++ regulatory T cells in chidhood with juvenile idiopathic arthritis[J]. Rheumatol Int, 2012, 32(5): 1147-1154.[9] Atfy M, Amr G E, Elnaggar A M, et al. Impact of CD4++CD25high regulatory T-cells and FoxP3 expression in the peripheral blood of patients with systemic lupus erythematosus[J]. Egypt J Immunol, 2009, 16(1): 117-126.[10] Morgan M E,Van Bilsen J H,Bakker A M, et al. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans [J]. Hum I mmunol, 2005, 66 (1): 13-20.[11] 张春梅.免疫性血小板减少症患者淋巴细胞亚群表达及其与血小板抗体、临床特征的相关性研究[J]. 中国煤炭工业医学杂志,2012,15(10):1524-1526.[12] 贲莹,张凤华,张冬.免疫细胞及相关细胞因子在格林-巴利综合征和实验性自身免疫性神经炎中的作用研究进展[J]. 解放军医药杂志,2013,25(2):14-16.[13] Harbuz R, Lespinasse J, Boulet S, et al. Identification of new FOXP3 mutations and prenatal diagnosis of IPEX syndrome[J]. Prenat Diagn, 2010, 30(11): 1072-1078.[14] Ban Y, Tozaki T, Tobe T, et al. The regulatory T cell gene FOXP3 and genetic susceptibility to thyroid autoimmunity: an association analysis in Caucasian and Japanese cohorts[J]. J Autoimmun, 2007, 28(4): 201-207.[15] Chen Y, Zhang H, Liao W, et al. FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China[J]. J Exp Clin Cancer Res, 2013, 32: 39.[16] Lan Y, Tang X S, Qin J, et al. Association of transcription factor FOXP3 gene polymorphism with genetic susceptibility to systematic lupus erythematosus in Guangxi Zhuang population[J]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2010, 27(4): 433-436.[17] Zhang J, Chen Y, Jia G, et al. FOXP3-3279 and IVS9+459 polymorphisms are associated with genetic susceptibility to myasthenia gravis[J]. Neurosci Lett, 2013, 534: 274-278.[18] Song P, Wang X W, Li H X, et al. Association between FOXP3 polymorphisms and vitiligo in a Han Chinese population[J]. Br J Dermatol, 2013,169(3):571-578.[19] 张媛,王成硕,张罗.FOXP3基因多态性与变应性鼻炎的相关性研究[J]. 中华耳鼻喉头颈外科学杂志,2010, 45(5): 397-400.[20] 娄玮,王成硕,张罗.调节性T细胞在过敏性鼻炎及抗原特异性免疫治疗中的作用[J]. 首都医科大学学报,2012,33(6):729-734.[21] Qiu X Y, Jiao Z, Zhang M, et al. Genetic association of FOXP3 gene polymorphisms with allograft rejection in renal transplant patients[J]. Nephrology (Carlton), 2012, 17(4): 423-430.[22] Wu Z G, You Z S, Zhang C, et al. Study on association of functional polymorphisms in Foxp3 gene with the susceptibility to unexplained recurrent spontaneous abortion [J]. Zhonghua Fu Chan Ke Za Zhi, 2011, 46(10): 763-768.[23] Fodor E, Garaczi E, Polyanka H, et al. The rs3761548 polymorphism of FOXP3 is a protective genetic factor against allergic rhinitis in the Hungarian female population[J]. Hum Immunol, 2011, 72(10): 926-929.[24] Gao L, Li K, Li F, et al. Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients[J]. J Dermatol Sci, 2010, 57(1): 51-56.[25] Jahan P, Cheruvu R, Tippisetty S, et al. Association of FOXP3 (rs3761548) promoter polymorphism with nondermatomal vitiligo: A study from India[J]. J Am Acad Dermatol, 2013, 69(2): 262-266.[26] Lin Y C, Lee J H, Wu A S, et al. Association of single-nucleotide polymorphisms in FOXP3 gene with systemic lupus erythematosus susceptibility: a case-control study[J]. Lupus, 2011, 20(2): 137-143.[27] Andre G M, Barbosa C P, Teles J S, et al. Analysis of FOXP3 polymorphisms in infertile women with and without endometriosis[J]. Fertil Steril, 2011, 95(7): 2223-2227.[28] D'Amico F, Skarmoutsou E, Marchini M, et al. Genetic polymorphisms of FOXP3 in Italian patients with systemic sclerosis[J]. Immunol Lett, 2013, 152(2): 109-113.[29] Metz T D, Nelson L M, Stoddard G J, et al. FOXP3 gene polymorphisms in preeclampsia[J]. Am J Obstet Gynecol, 2012, 206(2): 165.e1-6.[30] Xia G, Shah M, Luo X. Prevention of allograft rejection by amplification of Foxp3+CD4+CD25+ regulatory T cells[J]. Transl Res, 2009, 153(2): 60-70.[31] Tang Q, Bluestone J A, Kang S M. CD4+Foxp3+ regulatory T cell therapy in transplantation[J]. J Mol Cell Biol, 2012, 4(1): 11-21. |